Conclusion
SGLT2 inhibitors, acting through an insulin-independent manner, is
effective and safe in individuals with type 2 diabetes, and the case
here presented demonstrated its effectiveness in a patient with RMS.
Therefore, addressing other ways of reducing blood glucose that does not
depend on the action of insulin per se as SGLT2 inhibitors could be an
adjunctive therapeutic option in Rabson-Mendenhall Syndrome.